


MedAustron

PRISMAS-MAP
MEDAUSTRON PROPOSAL

Geneva, 19.09.2019

HISTORY



Kohlenstoffzentren weltweit: 11

(in Betrieb bis August 2017)

4

HIT Heidelberg
MIT Marburg
CNAO Pavia
MedAustron

Europa

7

Asien



© MedAustron • Daten: PTCOG, August 2017

Particle Therapy Centers in Europe: 21

(in operation by April 2018)

- Protons
- Protons & Carbon Ions



MedAustron in Austria

Wiener Neustadt




MedAustron Center



MedAustron in Austria

OWNERSHIP STRUCTURE




MedAustron Center



MedAustron in Austria

OWNERSHIP STRUCTURE



Our main task is the operation of the facility as an outpatient clinic (OPS).

Treatment of up to 1000 patients/year in full operation from Austria and foreign countries.

We focus on the further **development** of this treatment method and the **technology** behind (**Manufacturer Therapy Accelerator**).

Our facility is used for basic and translational research and provides non-clinical research area.

»EBG« stands for construction and operating company.

MEDAUSTRON FACILITY

Irradiation Rooms

Three rooms for patient treatment P252/C400

Research

dedicated non-clinical research room P800/C400

Ion Sources and LINAC

Three sources, RFQ, IH, Buncher, Debuncher, 7MeV/u


Synchrotron

$B\rho < 6.34 \text{ Tm}$, MTI, slow extraction



MEDAUSTRON – MEDICIS PROMED

- MedAustron was part of the Medicis Promed Network
- Contributed to TDR for implementation of C-11 use in european medical treatment facilities (MedAustron/CNAO)
- Studied options of integration in existing facilities



MEDAUSTRON AS A NETWORK PARTNER


MedAustron is aiming to:

- **become a center of excellence in the field of particle therapy**
- **broaden the range of indications and treatment methods**
- **increase performance and number of patients treated**
- **improve treatment quality**
- **follow up development of online radioisotope beam production**
- **provide access to a functioning treatment facility for testing of technology in clinical environment**

MEDAUSTRON NON-CLINICAL RESEARCH



Intrafraction Adaptive Radiation Therapy

- ▶ Intrafraction Surveillance Optimisation
- ▶ Markerless Real-Time Tumour Motion Imaging
- ▶ 4D Dose Calculation and Beam Delivery Optimisation
- ▶ End to End Testing
- ▶ Eye Treatment Solution for MedAustron





Magnetic Resonance Guided Particle Therapy

- ▶ Magnetic Resonance Workflow Development
- ▶ Dose Calculation
- ▶ Dosimetry






Interfraction Adaptive Radiation Therapy

- ▶ Quantitate Evaluation of mpMRI for Clinical Pilot Studies
- ▶ ART via In-Room CBCT
- ▶ Particle Therapy PET
- ▶ Monte Carlo Patient Specific QA



Energy Transfer Mechanisms and Applications in Biology and Physics

- ▶ Method Establishment
- ▶ Model Development for Microdosimetry
- ▶ Immunologically Hot Tumours
- ▶ Immunologically Cold Tumours



MEDAUSTRON IN A JOINT RESEARCH ACTIVITY

- ◉ **Proposal of a workpackage on Radioisotope application in particle therapy**
- ◉ **Potential aspects of the Workpackage:**
 - Study and improve PET imaging supported by radioisotope beams
 - Study and propose technologies for integration of radioisotope beams in european treatment facilities
 - Develop required components for radioisotope beams for particle therapy
-> eg high efficiency Ion Source
- **JRA - Ion Source Development**
 - Design (EB)IS suitable to fulfill the requirements for integration into existing treatment facilities
 - Prototyping and execution of preliminary tests
 - Integration of EBIS into existing facility and perform efficiency tests
 - Provide test facility for other ISOL developing institutions within PRISMA-MAP

REQUIREMENTS ON ION SOURCE

Intensity per pulse	$>10^{10}$	$^{11}\text{C}^{+4}$ Ions
Pulse repetition rate	< 0.2	Hz
Pulse length	2-30	μs
Emittance	< 180	pi mm mrad
Molecular break up	CO \rightarrow C	
Preferred charge state	C^{+4}	
Optional charge states	$\text{C}^{+5}, \text{C}^{+6}$	
Extraction Energy	8	keV/amu
Gas refilling	CO – continuous	
Gas release	pulsed heating	

- The source must provide 10^{10} particles during a synchrotron multiturn injection pulse which lasts 2-30 μs .
- A pulse is expected every 5-10 seconds
- In between pulses the source may remain on or off. Any outgoing beam will be blocked by a fast deflector.


TYPICAL CYCLE DEG100

- **Carbon cycle duration 9.5s**

Sector	Time Structure	Current [μA]	#Parts	Efficiencies
S2	DC	100	n.a.	n.a.
LEBT	25 μs	75	2.90E+09	n.a.
LI	25 μs	47	1.80E+09	62.1%
MEBT	25 μs	68	1.70E+09	94.4%
MR-CTS	debunched	n.a.	4.20E+08	24.7%
IR2	5s	1.22E-04	3.17E+08	75.5%

- **Total efficiency 10.9%**
- **Clinically DEG20 will be used!**
- **Typical treatment 1e9 carbons (varies a lot!!)**

TDR – C11 STUDY IN TREATMENT CENTER (MEDAUSTRON)



POTENTIAL IS - EBIS

High efficiency Ion Source (EBIS)

- **Accumulate ^{11}CO in a cryo trap which shall be integrated into the EBIS or in the close vicinity.**
- **Shock heat the cryo trap for pulsed release of ^{11}CO (see Dubna source)**
- **Inject $^{11}\text{C}^{+4}$ pulse (10^{10} , $<30\mu\text{s}$) into the existing accelerator structure (RFQ, IH-Tank, Synchrotron)**
- **Accelerator chain transport efficiency for Carbon-12 beams is $\approx 10\%$**

MEDAUSTRON JRA – ISOPROT:

- **High efficiency Ion Source (see JRA - OptION)**
 - Required for radioactive beam line (see Medicis Promed TDR for C-11 treatment facility)
 - Post-Doc + Student
 - MedAustron, CERN, DREEBIT, INFN-LNS, CNAO, update existing Ion Source design including cryotrap
 - Construction and first test (B-field, charge density, e-gun...)
 - Prepare MedAustron (S4/S5) beam line for Ion Source installation (beam optics, instrumentation, vacuum system)
 - Provide installation space at MedAustron (S4/S5) and integrate Ion Source in existing facility
 - Execute proof of principle test with non radioactive beams under authentic conditions
- Make new Ion Source commercially available for other treatment facilities (via industrial partners)
- Provide test facility for other ISOL developing institutions to enable radioisotope treatment in europe (gas purification, EM-separation,..)

GOAL - IMPACT



- **Start working towards full integration of C-11 beams in hadron therapy**
- **Provide test facility in clinical environment for developments towards this goal**
- **Demonstrate feasibility of ISOL integration in a treatment facility – Ion Source development/integration**
- **Develop and provide technology together with commercial partners to enable C-11 application in other european centers**

THANK YOU

For your attention!

MedAustron

REXEBIS TESTS




NON-CLINICAL RESEARCH

P 1 – Intrafraction Adaptive Radiation Therapy

WP 1: Intrafraction Surveillance Optimisation



WP 3: 4D Dose Calculation and Beam Delivery Optimisation




WP 2: Markerless Real-Time Tumour Motion Imaging



WP 4: End to End Testing


WP 5: Eye Treatment Solution for MedAustron



NON-CLINICAL RESEARCH

P 2 – Interfraction Adaptive Radiation Therapy


WP 1: Quantitate Evaluation of mpMRI for Clinical Pilot Studies




Before RT

4 months post RT

WP 3: Monte Carlo Patient Specific QA



WP 4: Particle Therapy PET



WP 2: ART via In-Room CBCT



NON-CLINICAL RESEARCH

P3 – Imaging with Ion Beams



continuation from the last research period

WP1: Monte Carlo Simulation & Dose Estimation

WP2: Proton Computed Tomography Set-Up & Data Taking

WP3: Stopping Power Reconstruction

WP4: Beam Delivery System Development



NON-CLINICAL RESEARCH




P 4 – Magnetic Resonance Guided Particle Therapy

continuation of the FWF Grant "MAGIG-PRO"

WP 1: MR Workflow Development

WP 2: Dose Calculation

WP 3: Dosimetry



NON-CLINICAL RESEARCH

P 5 – Energy Transfer Mechanisms and Applications in Biology and Physics

Physics Part





WP 1: Method Establishment

WP 2: Model Development for Microdosimetry

Biology Part

WP 3: Immunologically Hot Tumours

WP 4: Immunologically Cold Tumours



NON-CLINICAL RESEARCH


P 6 – Pre-Clinical Animal Research

WP 1: Commissioning of Animal Facility at MedAustron

WP 2: Evaluation and Characterisation of “In Vitro Tumour” Transplantation Techniques



WP 3: Construction and Dosimetry of Animal Irradiation Set-Ups



WP 4: Effects of Tumour Micro-Environment Composition on Tumour Control

WP 5: PET/CT Imaging to Monitor (Alterations in) Tumour Biology

